Premium
Inotuzumab ozogamicin in relapsed B‐cell acute lymphoblastic leukemia
Author(s) -
Thota Swapna,
Advani Anjali
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12862
Subject(s) - cd22 , blinatumomab , medicine , antibody drug conjugate , calicheamicin , oncology , b cell , chemotherapy , clinical trial , salvage therapy , lymphoblastic leukemia , acute lymphocytic leukemia , immunology , antibody , leukemia , monoclonal antibody
Despite an improved understanding of disease biology and the use of multi‐agent chemotherapy, the long‐term survival of adults with B‐cell acute lymphoblastic leukemia (B‐ALL) ranges from 35% to 50%. Management of patients with relapsed B‐ALL, a group characterized by dismal outcomes, poses a clinical challenge. To address this unmet need, novel therapeutics are being investigated in the setting of relapsed B‐ALL with encouraging results. CD22 is an important B‐cell antigen expressed in 80‐90% of B‐ALL cases. CD22 undergoes constitutive endocytosis with antibody ligation, making it an attractive biologic target for immunoconjugates. Inotuzumab ozogamicin (IO), a CD22‐targeted antibody‐drug conjugate demonstrated impressive single agent activity even among heavily pretreated relapsed B‐ALL patients. A recent randomized phase III clinical trial demonstrates superiority of IO over standard of care chemotherapy as first‐ or second‐line salvage therapy for relapsed B‐ALL. In this review, we summarize the preclinical and clinical data available to date using IO in relapsed B‐ALL.